Sort by
Previous Page Page 2 of 53 Next Page
  1. Original investigation

    Pregnancy-associated plasma protein-A is a stronger predictor for adverse cardiovascular outcomes after acute coronary syndrome in type-2 diabetes mellitus

    The risk prediction of pregnancy-associated plasma protein-A (PAPP-A) for future cardiovascular (CV) events post acute coronary syndrome (ACS) in patients with type-2 diabetes mellitus (T2DM) was investigated ...

    Wei-Ping Li, Moni B. Neradilek, Fu-Sheng Gu, Daniel A. Isquith, Zhi-Jun Sun, Xing Wu, Hong-Wei Li and Xue-Qiao Zhao

    Cardiovascular Diabetology 2017 16:45

    Published on: 5 April 2017

  2. Original investigation

    Glycemia and the cardioprotective effects of insulin pre-conditioning in the isolated rat heart

    While acute hyperglycemia has been shown to mitigate the beneficial effects of ischemic preconditioning, its effect on insulin-induced preconditioning remains unclear.

    Yosuke Nakadate, Hiroaki Sato, Takeshi Oguchi, Tamaki Sato, Akiko Kawakami, Tadahiko Ishiyama, Takashi Matsukawa and Thomas Schricker

    Cardiovascular Diabetology 2017 16:43

    Published on: 4 April 2017

  3. Review

    Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes

    Nowadays, obesity is seriously increasing in most of the populations all over the world, and is associated with the development and progression of high-mortality diseases such as type-2 diabetes mellitus (T2DM) a...

    N. González, Z. Moreno-Villegas, A. González-Bris, J. Egido and Ó. Lorenzo

    Cardiovascular Diabetology 2017 16:44

    Published on: 4 April 2017

  4. Original investigation

    Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial

    Sodium-glucose co-transporter-2 inhibitors (SGLT2i) reduce glucose levels, body weight, and blood pressure, possibly resulting in cardiovascular protection. In phase III trials, SGLT2i were shown to increase H...

    Gian Paolo Fadini, Benedetta Maria Bonora, Giancarlo Zatti, Nicola Vitturi, Elisabetta Iori, Maria Cristina Marescotti, Mattia Albiero and Angelo Avogaro

    Cardiovascular Diabetology 2017 16:42

    Published on: 4 April 2017

  5. Original investigation

    Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data

    Treatment of patients with type 2 diabetes mellitus (T2DM) and a history of cardiovascular (CV) disease or CV risk factors may present clinical challenges due to the presence of comorbid conditions and the use...

    Michael J. Davies, Katherine Merton, Ujjwala Vijapurkar, Jacqueline Yee and Rong Qiu

    Cardiovascular Diabetology 2017 16:40

    Published on: 21 March 2017

  6. Original investigation

    Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature

    We aimed to (1) assess the association between lipoprotein(a) [Lp(a)] concentration and incident type-2 diabetes in the Bruneck study, a prospective population-based study, and (2) combine findings with eviden...

    Ellie Paige, Katya L. Masconi, Sotirios Tsimikas, Florian Kronenberg, Peter Santer, Siegfried Weger, Johann Willeit, Stefan Kiechl and Peter Willeit

    Cardiovascular Diabetology 2017 16:38

    Published on: 21 March 2017

  7. Original investigation

    Association between obstructive sleep apnea severity and endothelial dysfunction in patients with type 2 diabetes

    Obstructive sleep apnea (OSA) and type 2 diabetes (T2D) are associated with endothelial dysfunction a main predictor of late cardiovascular (CV) events. Despite the high prevalence of OSA in patients with T2D,...

    Vanessa Bironneau, François Goupil, Pierre Henri Ducluzeau, Marc Le Vaillant, Pierre Abraham, Samir Henni, Séverine Dubois, Audrey Paris, Pascaline Priou, Nicole Meslier, Claire Sanguin, Wojciech Trzépizur, Ramaroson Andriantsitohaina, Maria Carmen Martinez and Frédéric Gagnadoux

    Cardiovascular Diabetology 2017 16:39

    Published on: 21 March 2017

  8. Original investigation

    Subclinical left ventricular diastolic dysfunction and incident type 2 diabetes risk: the Korean Genome and Epidemiology Study

    Subclinical left ventricular (LV) diastolic dysfunction in type 2 diabetes (T2D) is a common finding and represents an early sign of diabetic cardiomyopathy. However, the relationship between LV diastolic dysf...

    Juri Park, Jin-Seok Kim, Seong Hwan Kim, Sunwon Kim, Sang Yup Lim, Hong-Euy Lim, Goo-Yeong Cho, Ki-Chul Sung, Jang-Young Kim, Inkyung Baik, Kwang Kon Koh, Jung Bok Lee, Seung Ku Lee and Chol Shin

    Cardiovascular Diabetology 2017 16:36

    Published on: 14 March 2017

  9. Commentary

    Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group

    The 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group was held on the 20th–21st October 2016 in Munich. This second Summit was organized in ligh...

    Oliver Schnell, Eberhard Standl, Doina Catrinoiu, Stefano Genovese, Nebojsa Lalic, Jan Skra, Paul Valensi, Dario Rahelic and Antonio Ceriello

    Cardiovascular Diabetology 2017 16:35

    Published on: 11 March 2017

  10. Original investigation

    Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study

    Accumulation of epicardial fat (EF) is associated with increased cardio-metabolic risks and coronary events, independently of traditional cardiovascular risk factors. Therefore, the reduction of EF volume (EFV...

    Ryotaro Bouchi, Masahiro Terashima, Yuriko Sasahara, Masahiro Asakawa, Tatsuya Fukuda, Takato Takeuchi, Yujiro Nakano, Masanori Murakami, Isao Minami, Hajime Izumiyama, Koshi Hashimoto, Takanobu Yoshimoto and Yoshihiro Ogawa

    Cardiovascular Diabetology 2017 16:32

    Published on: 3 March 2017

  11. Original investigation

    The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activator dh404 protects against diabetes-induced endothelial dysfunction

    Vascular dysfunction is a pivotal event in the development of diabetes-associated vascular disease. Increased inflammation and oxidative stress are major contributors to vascular dysfunction. Nrf2, a master re...

    Arpeeta Sharma, Luddwi Rizky, Nada Stefanovic, Mitchel Tate, Rebecca H. Ritchie, Keith W. Ward and Judy B. de Haan

    Cardiovascular Diabetology 2017 16:33

    Published on: 3 March 2017

  12. Original investigation

    Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes

    Incretin-based agents, including dipeptidyl peptidase-4 inhibitors (DPP-4Is) and glucagon-like peptide-1 agonists (GLP-1As), work via GLP-1 receptor for hyperglycemic control directly or indirectly, but have d...

    Zeqing Zhang, Xi Chen, Puhan Lu, Jianhua Zhang, Yongping Xu, Wentao He, Mengni Li, Shujun Zhang, Jing Jia, Shiying Shao, Junhui Xie, Yan Yang and Xuefeng Yu

    Cardiovascular Diabetology 2017 16:31

    Published on: 1 March 2017

  13. Original investigation

    Cumulative increased risk of incident type 2 diabetes mellitus with increasing triglyceride glucose index in normal-weight people: The Rural Chinese Cohort Study

    Risk of type 2 diabetes mellitus (T2DM) is increased in metabolically obese but normal-weight people. However, we have limited knowledge of how to prevent T2DM in normal-weight people. We aimed to evaluate the...

    Ming Zhang, Bingyuan Wang, Yu Liu, Xizhuo Sun, Xinping Luo, Chongjian Wang, Linlin Li, Lu Zhang, Yongcheng Ren, Yang Zhao, Junmei Zhou, Chengyi Han, Jingzhi Zhao and Dongsheng Hu

    Cardiovascular Diabetology 2017 16:30

    Published on: 1 March 2017

  14. Original article

    Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis

    Physiologic determinants, such as pulse pressure [difference between systolic blood pressure (SBP) and diastolic BP (DBP)], mean arterial pressure (2/3 DBP + 1/3 SBP), and double product [beats per minute (bpm...

    Michael Pfeifer, Raymond R. Townsend, Michael J. Davies, Ujjwala Vijapurkar and Jimmy Ren

    Cardiovascular Diabetology 2017 16:29

    Published on: 27 February 2017

  15. Original investigation

    Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes

    Fewer circulating endothelial progenitor cells (EPCs) and increased plasma (C-term) stromal cell-derived factor 1α (SDF-1α), a substrate of DPP-4, are biomarkers, and perhaps mediators, of cardiovascular risk ...

    Alessandra Dei Cas, Valentina Spigoni, Monia Cito, Raffaella Aldigeri, Valentina Ridolfi, Elisabetta Marchesi, Michela Marina, Eleonora Derlindati, Rosalia Aloe, Riccardo C. Bonadonna and Ivana Zavaroni

    Cardiovascular Diabetology 2017 16:27

    Published on: 23 February 2017

  16. Original article

    A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation

    The sodium–glucose cotransporter 2 inhibitor, dapagliflozin, has been shown to improve diabetic control and reduce blood pressure in patients with type 2 diabetes mellitus. Its effects on micro- and macrovascu...

    Christian Ott, Agnes Jumar, Kristina Striepe, Stefanie Friedrich, Marina V. Karg, Peter Bramlage and Roland E. Schmieder

    Cardiovascular Diabetology 2017 16:26

    Published on: 23 February 2017

  17. Review

    Diagnostic approaches for diabetic cardiomyopathy

    Diabetic cardiomyopathy (DCM) is a cardiac dysfunction which affects approximately 12% of diabetic patients, leading to overt heart failure and death. However, there is not an efficient and specific methodolog...

    A. Lorenzo-Almorós, J. Tuñón, M. Orejas, M. Cortés, J. Egido and Ó. Lorenzo

    Cardiovascular Diabetology 2017 16:28

    Published on: 23 February 2017

  18. Original article

    Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients

    Vascular calcification (VC) is common in type 2 diabetes, and is associated with cardiovascular complications. Recent preclinical data suggest that metformin inhibits VC both in vitro and in animal models. How...

    Aurélien Mary, Agnes Hartemann, Sophie Liabeuf, Carole Elodie Aubert, Salim Kemel, Joe Elie Salem, Philippe Cluzel, Aurélie Lenglet, Ziad A. Massy, Jean-Daniel Lalau, Romuald Mentaverri, Olivier Bourron and Saïd Kamel

    Cardiovascular Diabetology 2017 16:24

    Published on: 15 February 2017

  19. Original investigation

    DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes

    Use of dipeptidyl peptidase-4 inhibitors (DPP4-i) for the treatment of type 2 diabetes (T2D) has been associated with a possible increase in the risk for heart failure (HF). B-type natriuretic peptide (BNP), w...

    Gian Paolo Fadini, Benedetta Maria Bonora, Mattia Albiero, Martina Zaninotto, Mario Plebani and Angelo Avogaro

    Cardiovascular Diabetology 2017 16:22

    Published on: 10 February 2017

  20. Original investigation

    Third generation drug eluting stent (DES) with biodegradable polymer in diabetic patients: 5 years follow-up

    To report the long-term safety and efficacy data of a third generation drug eluting stent (DES) with biodegradable polymer in the complex patient population of diabetes mellitus after a follow-up period of 5 ...

    Marcus Wiemer, Sinisa Stoikovic, Alexander Samol, Zisis Dimitriadis, Juan M. Ruiz-Nodar, Ralf Birkemeyer, Jacques Monsegu, Gérard Finet, David Hildick-Smith, Damras Tresukosol, Enrique Garcia Novo, Jacques J. Koolen, Emanuele Barbato and Gian Battista Danzi

    Cardiovascular Diabetology 2017 16:23

    Published on: 10 February 2017

    The Erratum to this article has been published in Cardiovascular Diabetology 2017 16:59

  21. Original investigation

    Advanced glycation end products induce brain-derived neurotrophic factor release from human platelets through the Src-family kinase activation

    Brain-derived neurotrophic factor (BDNF) exerts beneficial effects not only on diabetic neuropathies but also on cardiovascular injury. There is argument regarding the levels of serum BDNF in patients with dia...

    Kazuo Furukawa, Ichiro Fuse, Yuriko Iwakura, Hidekazu Sotoyama, Osamu Hanyu, Hiroyuki Nawa, Hirohito Sone and Nobuyuki Takei

    Cardiovascular Diabetology 2017 16:20

    Published on: 8 February 2017

Previous Page Page 2 of 53 Next Page